Suzhou, China – August 11, 2025 – Crystal Pharmatech Co., Ltd. announced that its China Suzhou CRO business unit has successfully completed the re-assessment, scope expansion, and laboratory address change review conducted by the China National Accreditation Service (CNAS) for Conformity Assessment. Following the review, the company was issued an updated Laboratory Accreditation Certificate (Registration No. CNAS L18115), reaffirming the quality, technical rigor, and compliance of its testing operations.
Laboratory Accreditation Certificate
Backed by a robust quality management system, advanced instrumentation, and a highly skilled technical team, Crystal Pharmatech achieved both reaccreditation and expansion of its accredited testing scope. This milestone further strengthens the company's position as a trusted partner in pharmaceutical analytics, ensuring precise, reliable results that support drug development while creating broader value for clients and society.
Crystal Building
The current accreditation now covers nine testing capabilities, including three newly added items:
| 1. | Moisture | (coulometric method) |
| 2. | Identification | (powder X-ray diffraction) |
| 3. | Crystallinity | |
| 4. | Thermal analysis | |
| 5. | Particle size and particle-size distribution | |
| 6. | Residual solvent analysis | (new: quantitative analysis) |
| 7. | Hygroscopicity | (new) |
| 8. | Dynamic water-vapor sorption | (new) |
| 9. | Structure confirmation | (single-crystal X-ray diffraction analysis) |
The Onsite Review
"The reaccreditation marks a new starting point for us," the company noted. "We remain committed to strengthening internal quality systems, enhancing laboratory operations, and continually improving analytical capabilities to better serve our clients and the industry."
The outcome of the CNAS review confirms three key achievements: continued compliance with technical requirements for all existing items, successful expansion to meet increasing demand for diverse testing services, and validation of the stability and performance of the company's new laboratory facilities. Moving forward, the CRO unit will continue to support pharmaceutical R&D, manufacturing, and quality assurance by providing impartial, standardized, and efficient services that ensure the safety, efficacy, and quality of medicines.
